

1 **Association of IL-6 -174G/C and IL-10- 1082G/A Polymorphisms and Risk of**
2 **Chronicity of Hepatitis B Infection in Sudanese End Stage Renal Disease**
3 **Patients**

4 Omer B. Mohamedsalih¹, Waleed A. Hussain^{2*}

5 ¹ *Department of Molecular biology, Faculty of Medical Laboratory Sciences*

6 *Alneelain University, Khartoum- Sudan.*

7 ² *Department of Immunology and Molecular biology, Faculty of Medical Laboratory Sciences*

8 *Alneelain University, Khartoum- Sudan.*

9 *Corresponding author: Waleed Abdelateif Hussain

10 waleed.86h@gmail.com

11 +249912257223

12 *Department of Immunology and Molecular biology, Faculty of Medical Laboratory Sciences*

13 *Alneelain University, Khartoum- Sudan.*

14

15 **Abstract**

16 **Background:** Overt hepatitis B virus (HBV) infection is defined as infection with detectable
17 surface antigen (HBsAg) in patient's blood. End stage renal disease (ESRD) patients who are on
18 maintenance hemodialysis (HD) are considered to be strong candidates for HBV infection due to
19 prolonged vascular access via HD procedure. In addition, the differences in host immune response
20 can be one of the reasons for the various clinical presentations of HBV infection. Polymorphisms
21 of genes encoding the pro-inflammatory and anti-inflammatory cytokines, which are responsible
22 for regulation of the immune response, can affect the clinical presentation of the infection.
23 Particularly, the polymorphisms of the genes encoding cytokines such as interleukin 6 (IL6) and
24 interleukin 10 (IL10).

25 **Aim:** This current study aimed to compare serum levels and allelic variant of IL-6 -174G/C and
26 IL-10- 1082G/A polymorphisms in patients with overt hepatitis B and end stage renal disease
27 hepatitis B patients in Khartoum State- Sudan.

28 **Method:** Case control study has been conducted to detect the IL-6 -174G/C and IL-10- 1082G/A
29 polymorphisms using SSP-PCR and serum level of IL6 and IL10 using ELISA in 68 from
30 Hepatitis B patient (37 overt hepatitis B patients and 31 end stage renal disease hepatitis B patients

31 **Result:** The result showed that there was no statistically difference in IL6 (174G/C) and IL10
32 (1082G/A) Allelic frequencies (P. value = .738, .194 respectively), Serum level (P. value = 0.36,
33 .179 respectively) between two groups. In addition there is no significant correlation between the
34 IL6 (174G/C) and IL10 (1082G/A) and serum level in study groups.

35 **Conclusion:** The Allelic Variant of IL-6 -174G/C and IL-10- 1082G/A Polymorphisms and
36 serum levels could not play apart in complication of hepatitis B in end stage renal disease
37 patients.

38 **Keywords:** IL-6 -174G/C, IL-10- 1082G/A, Polymorphisms, End Stage Renal Disease, Chronic
39 Hepatitis B, Khartoum, Sudan.

40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61

62 **Introduction**

63 Hepatitis B virus (HBV) is a hepatotropic, small, enveloped DNA virus that belongs to the
64 Hepadnaviridae family and causes an acute or chronic infection in humans. Chronic hepatitis B
65 virus (HBV) infection represents a major global health problem, affecting an estimated 257-291
66 million persons worldwide and is associated with substantial morbidity and mortality because of
67 clinical complications, such as liver cirrhosis and hepatocellular carcinoma [1].

68 In Sudan a recent systematic review and meta-analysis including 14 studies with 5848
69 participants have been conducted, revealing that HBV seroprevalence rates ranged from 5.1 to
70 26.8% with an overall pooled prevalence of 12.1%. According to study findings, Khartoum State
71 had the highest prevalence of HBV infection in Sudan with a proportion of 12.7% [2].

72 Among many groups susceptible to HBV infection, patients with end-stage renal disease
73 (ESRD) who are on maintenance haemodialysis (HD) are considered to be strong candidates for
74 HBV infection due to prolonged vascular access via HD procedure at HD units where the
75 nosocomial transmission of this virus is well documented (Ayatollahi, 2016) [3]. In addition, the
76 impaired immune response of HD patients puts this population under serious risk of Hepatitis B
77 [4].

78 Unlike the appearance of this infection in immune-competent individuals, HBV infection
79 usually tends to be chronic in HD patients due to the immunosuppressive nature of ESRD [5].
80 Chronic HBV infection has three distinct states of chronicity, which can be differentiated
81 serologically. The first one is chronic Hepatitis B characterized by detectable HBsAg in the serum
82 for six months or more known as overt Hepatitis B. The second is an inactive HBV carrier in which
83 the HBsAg is detectable in the serum with negative HBeAg. The third one is an unusual clinical
84 entity known as occult Hepatitis B infection (OBI) [6].

85 The challenges in the area of HBV-associated disease like ESRD are the dearth of
86 knowledge in predicting outcome and progression of HBV infection and need to understand them
87 molecular, cellular, immunological, and genetic basis of assorted disease manifestations related to
88 HBV infection. The differences in host immune response can be one of the reasons for the various
89 clinical presentations of HBV infection. Polymorphisms of genes encoding the pro-inflammatory
90 and anti-inflammatory cytokines, which are responsible for regulation of the immune response,
91 can affect the clinical presentation of the infection. Particularly, the polymorphisms of the genes
92 encoding cytokines such as interleukin IL-6 and IL-10 [7].

93 **Material and methods**

94 **Study design and Sample collection**

95 A case control study was conducted at Khartoum state, Sudan. Blood specimen from chronic
96 hepatitis B patient (37 overt hepatitis B patients as control group and 31 end stage renal disease
97 hepatitis B patients as case group) was collected in EDTA Containers and store at -20 °c until
98 processing.

99 **Laboratory work**

100 **DNA extraction**

101 The DNA was extracted from 300 µl of blood sample using (G-spin™
102 Total DNA Extraction Mini Kit, intron biotechnology – Korea) according to manufacture
103 instruction.

104 **Determination of DNA quality and purity**

105 Part of the DNA solution mixed with loading dye 5 in 1 and DNA quality and purity
106 determined using gel electrophoresis. DNA transferred into 1 ml Eppendorf tube [8].

107 **DNA storage:** DNA was transferred into 1ml Eppendorf tube and preserved at -20°C until PCR
108 process.

109 **Polymerase chain**

110 **Interleukin-6 (-174G/C) and Interleukin-10(-1082 G/A) genotyping**

111 The SSP-PCR (sequence-specific primer-polymerase chain reaction) method applied for
112 genotyping; PCR mixture of 20 µl prepared from master mix tubes (5X FIREPOL®, Solis bioDyne
113 – Estonia) for each sample. Genomic DNA amplified in two different PCRs for each
114 polymorphism; each reaction employed ageneric antisense primer and one of the two allele-
115 specific sense primers (see table 3.1, 3.2). To assess the success of PCR amplification in both
116 reactions. The PCR reaction carried out in a Thermal Cycler (Techne, UK), with the following
117 programs: 1min at 95C followed by 35 cycles of 30 sec at 95°C, 30 sec at 58°C, 30 sec at 72°C,
118 with 5min at 72°C as final extension [9].

119 for Interleukin-10 genotyping , 1min at 95C followed by 35 cycles of 30 sec at 95°C, 30
120 sec at 55.5°C, 30 sec at 72°C, with 5min at 72°C as final extension for Interleukin-6 genotyping
121 [8].

122

123

124

125

126 **Table (1) Primer Sequences Used for the IL-6 SSP Genotyping Method:**

Primer position	Primer sequence	Product size
IL6(-174) C primer	5'-CCC CTA GTT GTG TCT TGC C-3'	240bp
IL6(174) G primer	5'-CCC CTA GTT GTG TCT TGC G-3'	240bp
IL6 Generic	5'-GCC TCA GAG ACA TCA CCA GTC C-3'	240bp

127

128 **Table (2) Primer Sequences Used for the IL-10 SSP Genotyping Method:**

Primer position	Primer sequence	Product size
IL-10 common (reverse)	5'-CAGCCCTTCCATTTTACTTTC-3'	550 bp
IL-10 G (forward)	5'-TACTAAGGCTTCTTTGGGAG-3'	550 bp
IL-10 A (forward)	5'-CTACTAAGGCTTCTTTGGGAA-3'	550bp

130 **Demonstration of PCR product:**

131 Five µl of the PCR product (ready to load) was electrophoresed on 1.5% agarose gel, and stained
132 with ethidium bromide, 1X TBE buffer will be used as a running buffer. The Voltage applied to
133 the gel will be 100 volt with time duration of 30 minutes. 100 pb DNA ladder will be used as
134 molecular weight marker with each patch of samples Finally, PCR product will be demonstrated
135 by gel documentation system [8].

136 **IL10 and IL6 serum level estimation**

137 Patients serum were tested for the presence of IL-6 and IL-10 using commercially available ELISA
138 sets for human IL-10 (ELISA MAX Standard set, #430601, BioLegend), IL-6 (ELISA MAX
139 Standard set, #430501, BioLegend), following the protocols supplied by the manufacturers.

140 **Data analysis:**

141 The data analyzed using the SPSS computer program version 21. Independent sample – T.
142 Test was used to determine the difference in genotype frequencies among study groups, the mean

143 and stander deviation was applied for Serum level and ANOVA test with mean to correlate the
144 genotype frequencies and serum level. The data presented in tables and figures.

145 **Result**

146 In the present study we compare Serum levels and Allelic Variant of IL-6 -174G/C and IL-
147 10- 1082G/A Polymorphisms in 31 Patients with Overt Hepatitis B and 37 End Stage Renal
148 Disease Hepatitis B patients. The study was carried out in Khartoum state in Sudan.

149 Table 4.1 show that there was no statistically difference in IL6 (174G/C) Genotypes (CC,
150 CG and GG) frequencies between overt Hepatitis B patients and end stage renal disease (ESRD)
151 hepatitis B patients (P. value = 0.738).

152 Table 4.2 show that there was no statistically difference in IL10 (1082G/A) Genotypes
153 (AA, GG and GA) frequencies between overt Hepatitis B patients and end stage renal disease
154 hepatitis B patients (P. value = 0.194).


155 Table 4.3 show that there was no statistically difference in IL6 serum levels between overt
156 Hepatitis B patients and end stage renal disease hepatitis B patients (P. value = 0.36)

157 Table 4.4 show that there was no statistically difference in IL10 serum levels between overt
158 Hepatitis B patients and end stage renal disease hepatitis B patients (P. value = 0.179).

159 Table 4.5 show that there was no statistically significant correlation between IL6
160 (174G/C) and serum level in Overt Hepatitis B patients and end stage renal disease hepatitis B
161 patients (P. value = 0.536, 0.449 respectively).


162 Table 4.6 show that there was no statistically significant correlation between IL10
163 (1082G/A) and serum level in Overt Hepatitis B patients and Overt Hepatitis B patients (P. value
164 = 0.092, 0.229 respectively).

165



166

167 **Figure 4.1:** A representative Agarose (2%) gel electrophoresis of SS-PCR product (550bp) for
168 genotyping of Interleukin-10(-1082 G/A); M: 50bp DNA marker, Lane 1, 3: represent
169 Heterozygous mutant individuals (GA), Lane 2: represent Homozygous mutant individual (AA).



170

171 **Figure 4.2:** A representative Agarose (2%) gel electrophoresis of SS-PCR product (200bp) for
172 genotyping of Interleukin-6 (-174G/C); M: 100bp DNA marker, lane 1: represent invalid sample,
173 Lane 2, 4: represent Homozygous mutant individuals (CC), lane3: represent Homozygous wild
174 individual (GG) and lane5, 6, 7: represent Heterozygous mutant (GC).

175

176

177 **Table 4.1 IL6 (174G/C) Genotypes frequencies among study groups.**

Study groups	IL6 Genotype frequency			Total	P. value
	CC	GG	GC		
ESRD Hepatitis B patients	5 (16%)	11 (36%)	15 (48%)	31 (100%)	0.738
Overt Hepatitis B patients	6 (16%)	15 (41%)	16 (43%)	37 (100%)	

178

179 **Table 4.2 IL10 (1082G/A) Genotypes frequencies among study groups.**

Study groups	IL10 Genotype frequency			Total	P. value
	AA	GG	GA		
ESRD Hepatitis B patients	4 (13%)	19 (61%)	8 (26%)	31 (100%)	0.194
Overt Hepatitis B patients	2 (5%)	21 (67%)	14 (38%)	37 (%)	

180 **Table 4.3 IL6 Serum Level among study groups.**

Study groups	IL6 Serum Level (Mean ± STD)	P. value
ESRD Hepatitis B patients	15.390 ±18	0.36
Overt Hepatitis B patients	9.325 ±10	

181

182 **Table 4.4 IL10 Serum Level among study groups.**

Study groups	Serum Level (Mean ± STD)	P. value
ESRD Hepatitis B patients	6.304 ± 4	0.179
Overt Hepatitis B patients	3.670 ±6	

183

184 **Table 4.5 Correlation between IL6 (174G/C) polymorphisms and serum level in study**
185 **groups.**

186

187

188

189

190

Study groups	IL6 Serum Level (Mean ± STD)			P. value
	CC	GG	GC	
ESRD Hepatitis B patients	5.2 ±5	11.7±14	8.5±8.2	.449
Overt Hepatitis B patients	6.8± 9	18± 20	16±19	.536

191 **Table 4.5 Correlation between IL10 (1082G/A) polymorphisms and serum level in study**
192 **groups.**

Study groups	IL10 Serum Level (Mean ± STD)			P. value
	CC	GG	GC	
ESRD Hepatitis B patients	11± 13	3.5 ±5.4	2.8± 6.2	.229
Overt Hepatitis B patients	2.70 ± 1.9	6 ± 4.7	8.7 ± 4.1	.092

194 **Discussion**

195 Hepatitis B virus (HBV) infection commonly induces immune reactive inflammation,
196 which results in continuous liver tissue damage and progression of liver fibrosis to cirrhosis or
197 hepatocellular carcinoma especially in immunocompromised patients like End stage renal disease
198 patients [10].

199 Cytokines and particularly IL6 and IL10 are key regulatory elements of innate immunity
200 against HBV infection and can affect the stage of disease. Immune dysfunction and the impaired
201 hepatitis B vaccination response are complications of chronic renal failure that are tightly
202 associated with inflammation induced by uremia and blood-membrane contacts [11].

203 Interleukin IL-6 are counter regulated by IL-10 with a large inter-individual variability.
204 Part of the variability of cytokine production is genetically determined since polymorphisms in the
205 cytokine gene promoters lead to high or low production [12].

206 The aim of this study was to compare Allelic variant of IL-6 -174G/C and IL-10- 1082G/A
207 Polymorphisms and their serum levels in patients with overt hepatitis B and end stage renal Disease
208 hepatitis B patients in Khartoum State- Sudan, the result illustrated that the Allelic Variant of IL-
209 6 -174G/C and IL-10- 1082G/A Polymorphisms could not play apart in complication of chronic
210 Hepatitis B in End stage renal disease patients, this finding is similar to meta- analysis by Ye Feng
211 et al who conclude that the IL-6 -174G/C polymorphism has no significant correlation with the
212 susceptibility risk of ESRD, and may not be a risk factor for ESRD [13].

213 Also Buckham et al. and Kandil et al. suggest that, there is no correlation between IL-6
214 gene polymorphism and ESRD [14, 15].

215 In return regarding the role of IL-6 -174G/C polymorphism in Chronic hepatitis B (CHB)
216 and HBV related liver disease the meta-analysis done by Chang Lei et al illuminated that the IL-6
217 -174G/C polymorphism did not play part in susceptibility to CHB [16].

218 In regard to the influence of IL-10- 1082G/A Polymorphisms on immune function of CHB
219 the study by Zhang et al showed no significant difference between IL-10- 1082G/A
220 Polymorphisms and patient with CHB [17]. In contrast many experimental and meta-analysis
221 studies suggest that there is association between IL-6 -174G/C and IL-10- 1082G/A
222 Polymorphisms and their serum level and immune function of CHB patient with ESRD but all
223 these finding awaits more verification because we do not know how the intronic variant affect the
224 expression and level of theses cytokines.

225 We believe that our study has some limitation. Firstly, the sample size is relatively small,
226 the race subgroups are missed and the collected data are not comprehensive. Finally, the influence
227 of these promoters polymorphism on gene expression was not directly analyzed.

228 **Conclusion**

229 We conclude that the allelic variant of IL-6 -174G/C and IL-10- 1082G/A polymorphisms
230 and serum levels could not play apart in chronicity of hepatitis B in end stage renal disease patients.

231 **Recommendations**

- 232 1. Direct evaluation of gene expression for these promoters polymorphism.
- 233 2. Conduct more studies regarding the intronic variant effect on gene expression and level of
234 theses cytokines.

235 **Acknowledgment**

236 Thanks to Allah almighty who enable me to stand and attend this moments, our thanks
237 extend to all concerned persons who co-operated with me in this regard.

238 **Conflict of interest statement**

239 All authors have no competing interest declared.

240 **Funding**

241 This work did not receive any specific grant from funding agencies in the public,
242 commercial, or not-for-profit sector.

243 **Ethical consideration**

244 This study was approved by the Ethical Committee of Scientific Research Deanship
245 Alneelain University, and informed consent obtained from each participant before sample
246 collection.

247

248

249

250

251

252

253 **References**

- 254 [1] **Lim, J. K., Nguyen, M. H., Kim, W. R., Gish, R., Perumalswami, P., & Jacobson,**
255 **I. M. (2020).** Prevalence of Chronic Hepatitis B Virus Infection in the United
256 States. *The American journal of gastroenterology*, *115*(9), 1429–1438.
- 257 [2] **Badawi, M.M., Atif, M., & Mustafa, Y. (2018).** Systematic review and meta-analysis
258 of HIV, HBV and HCV infection prevalence in Sudan. *Virology Journal*, *15*.
- 259 [3] **Ayatollahi, J., Jahanabadi, S., Sharifyazdi, M., Hemayati, R., Vakili, M., &**
260 **Shahcheraghi, S.H. (2016).** The Prevalence of Occult Hepatitis B Virus in the
261 Hemodialysis Patients in Yazd, Iran. *Acta medica Iranica*, *54* (12), 784-787.
- 262 [4] **Saijo, T., Joki, N., Inishi, Y., Muto, M., Saijo, M., & Hase, H. (2015).** Occult
263 hepatitis B virus infection in hemodialysis patients in Japan. *Therapeutic apheresis and*
264 *dialysis : official peer-reviewed journal of the International Society for Apheresis, the*
265 *Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy*, *19*(2), 125–
266 130.
- 267 [5] **Fontenele, A. M., Filho, N. S., & Ferreira, A. S. (2013).** Occult hepatitis B in patients
268 on hemodialysis: a review. *Annals of hepatology*, *12*(4), 527–531.
- 269 [6] **Musa, M. D., & Ateya, H. K. (2020).** Prevalence of overt and occult hepatitis B virus
270 infections among 135 haemodialysis patients attending a haemodialysis centre at Al-
271 Nasiriyah city, Iraq. *Iranian journal of microbiology*, *12*(5), 475–482.
- 272 [7] **Tunçbilek S. (2014).** Relationship between cytokine gene polymorphisms and chronic
273 hepatitis B virus infection. *World J Gastroenterol*, *20*:6226–35.
- 274 [8] **Sharif OM, Hassan R, Mohammed Basbaeen AA, Mohmed AH, Ibrahim IK.**
275 **(2019).** Interleukin-10 (1082G/A) Polymorphism is Associated with Susceptibility of
276 Acute Myeloid Leukemia Patients in Sudanese Population. *Asian Pac J Cancer Prep*,
277 *20*(7):1939-1943.
- 278 [9] **Sarhang H. Azeez and Suhaila N. Darogha. (2019).** Proinflammatory cytokine IL-6
279 -174G/C (rs1800795) gene polymorphism among patients with chronic renal
280 failure. *Invest Clin.*; *60*(3), 221 - 232.
- 281 [10] **Tan, A., Koh, S., & Bertoletti, A. (2015).** Immune Response in Hepatitis B Virus
282 Infection. *Cold Spring Harbor perspectives in medicine*, *5*(8), a021428.

- 283 [11] **Zhang PA, LiY, Yang XS. (2006).** Associated study on interleukin 10 gene
284 promoter polymorphisms related to hepatitis B virus infection in Chinese population.
285 *Zhonghua Yi Xue Yi Chuan Xue Za Zhi.* 2006; 23(4): 410-14.
- 286 [12] **Girndt, M., Sester, U., Sester, M., Deman, E., Ulrich, C., Kaul, H., & Köhler,**
287 **H. (2001).** The interleukin-10 promoter genotype determines clinical immune function
288 in hemodialysis patients. *Kidney international*, 60 (6), 2385-91.
- 289 [13] **Feng Y, Tang Y, Zhou H, Xie K. (2017).** A meta-analysis on correlation between
290 interleukin-6 -174G/C polymorphism and end-stage renal disease. *Renal Failure*,
291 39(1):350-356.
- 292 [14] **Buckham TA, McKnight AJ, Benevente D, Courtney AE, Patterson CC,**
293 **Simmonds M. (2010).** Evaluation of five interleukin genes for association with end-
294 stage renal disease in white Europeans. *Am J Nephrol*; 32:103–108.
- 295 [15] **Kandil MH, Magour GM, Khalil GI, Maharem DA, Nomair AM. (2013).**
296 Possible association of interleukin-1beta (-511C/T) and interleukin-6 (-174G/C) gene
297 polymorphisms with atherosclerosis in end stage renal disease Egyptian patients on
298 maintenance haemodialysis. *Egypt. J Med Hum Genet*; 14:267–275.
- 299 [16] **Chang, L., Lan, T., Wu, L., Li, C., Yuan, Y., & Liu, Z. (2015).** The association
300 between three IL-6 polymorphisms and HBV-related liver diseases: a meta-
301 analysis. *International journal of clinical and experimental medicine*, 8(10), 17036–
302 17045.
- 303 [17] **Zhang PA, LiY, Yang XS. (2006).** Associated study on interleukin 10 gene
304 promoter polymorphisms related to hepatitis B virus infection in Chinese population.
305 *Zhonghua Yi Xue Yi Chuan Xue Za Zhi.* 2006; 23(4): 410-14.